HIV infection and cardiovascular diseases Matthew S. Freiberg, MD, MSc University of Pittsburgh School of Medicine and Graduate School of Public Health.

Slides:



Advertisements
Similar presentations
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Advertisements

Should we treat HIV Controllers ? IAS 2013 Pr Olivier Lambotte Department of internal medicine and clinical immunology Bicêtre Hospital, University Paris.
Delay from Testing HIV Positive until First HIV Care for Drug Users: Adverse Consequences and Possible Solutions Barbara J Turner MD, MSEd* John Fleishman.
The hidden HIV epidemic: what do mathematical models tell us? The case of France Virginie Supervie, Jacques Ndawinz & Dominique Costagliola U943 Inserm.
Biomarkers of Inflammation, Coagulation and Monocyte Activation Are Strongly Associated with the VACS Index among Veterans on cART Amy Justice* 1,2, Matthew.
Why is inflammation elevated in treated HIV infection and why does it matter? Steven G. Deeks Professor of Medicine University of California, San Francisco.
Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Abstract: WEABO205. HIV infection was associated with an increased risk of hip fracture,
Cardiovascular Complications of HIV Mark Boyd MD, FRACP The Kirby Institute for infection and immunity in society 7 th IAS Conference Kuala Lumpur, Malaysia.
Protective HLA Class I alleles are associated with reduced immune activation in Primary HIV infection Elizabeth Hamlyn 1, Stephen Hickling 2, Abdel Babiker.
Role of Antiretroviral Therapy, Viral Replication, and HIV Infection in Atherosclerosis Priscilla Y. Hsue, Peter W. Hunt, Jeffrey N. Martin, Amanda Schnell,
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2010.
Cardiovascular Disease: Predicting Risk and Monitoring Outcomes Monica R. Shah, MD, FACC NHLBI AIDS Coordinator Conference on Retroviruses and Opportunistic.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
HDL Particles but not LDL Particles Predict Cardiovascular Disease Events in HIV Patients: Results from Strategies for Management of ART Study (SMART)
Long Term Management of HIV Infection in Aging Adults: Current Challenges, Future Strategies Andrew Zolopa, MD Stanford University.
HIV Early Treatment Project Groups 1 and 2 n Among HIV-infected participants in sub-Saharan Africa, does initiation of antiretroviral treatment (ART) at.
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
ACCORD - Action to Control Cardiovascular Risk in Diabetes ADVANCE - Action in Diabetes to Prevent Vascular Disease VADT - Veterans Administration Diabetes.
Risk of serious disease and death in people with HIV viral suppression on ART: an epidemiologic perspective The Lancet and Cell Meeting What Will it Take.
Patient Empowerment Impacts Medication Adherence among HIV-Positive Patients in the Veteran’s Health Administration Tan Pham 1,2,3, Kristin Mattocks 1,2,
VBWG CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial.
The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected Persons The Effect of Syphilis Co-infection on Clinical Outcomes in HIV-Infected.
Factors associated with Mortality in the Study of Fat Redistribution and Metabolic Change in HIV infection Leslie Modrich 1, Rebecca Scherzer 1,2, Andrew.
Fatal and Non-fatal Hepatic Failure in HIV-infected versus HIV-uninfected Persons Enrolled in Kaiser Permanente California (KP), a Large Managed Care Organization.
Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Trial MEGA Trial Presented at The American Heart Association.
Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY.
#735 KA Lichtenstein 1, C Armon 2, K Buchacz 3, AC Moorman 3, KC Wood 2, JT Brooks 3, and the HOPS Investigators 1 University of Colorado Health Sciences.
Impact of Highly Active Antiretroviral Therapy on the Incidence of HIV- encephalopathy among perinatally- infected children and adolescents. Kunjal Patel,
T-Cell Senescence & Inflammation HIV Research Catalyst Forum, April
David Dowdy, Elvin Geng, Katerina Christopoulos, James Kahn, C. Bradley Hare, Daniel Wlodarczyk, Diane Havlir Internal Medicine Residency Program, UCSF.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
Introductory talk D Costagliola.
The role of treatment versus disease in causing premature non-AIDS morbidity Judith S. Currier, MD University of California, Los Angeles.
VBWG Predictor of CV Events and Mortality in Postmenopausal Women: Leukocyte Count.
Association of C-Reactive Protein and Acute Myocardial Infarction in HIV-Infected Patients Virginia A. Triant, MD, MPH, James B. Meigs, MD, MPH, and Steven.
Evidence for the link between markers of inflammation, coagulation and immune activation and end organ disease Session: Immune Activation/Inflammation.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
HCV Co-infection is Associated with a High Risk of Osteoporotic Fractures Among HIV Patients Roger Bedimo, MD; Henning Drechsler, MD; Song Zhang, PhD;
Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.
Can early antiretroviral therapy fully restore health? Workshop on Pathogeneses and Management of Long-Term Complications of ART IAS Conference, Rome July.
Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
Figure 2: Trends in currently prescribed antiretroviral therapy % prescribed HAART increased from 74% to 83% Trends in ART use, HIV viral load, and CD4.
Weekly Alendronate Safe and Effective at Increasing Bone Mineral Density in HIV-Infected Persons on Antiretroviral Therapy Slideset on: McComsey GA, Kendall.
A Survival Comparison between HIV+ U.S.-born Latinos and Foreign-born Latinos in Houston, Texas Raouf Arafat, MD, MPH, Adebowale Awosika- Olumo.
Assessment of cardiovascular risk in a 3-year- cohort of HIV-infected patients of Sub-Saharan origin living in France or Côte d’Ivoire and starting antiretroviral.
Cutrell A, Hernandez J, Brothers C et al Is abacavir (ABC)-containing combination antiretroviral therapy (CART) associated with myocardial infarction.
Acute Renal Failure in HIV- Infected Individuals Greatly Increases Risk for In-Hospital Mortality Slideset on: Wyatt CM, Arons RR, Klotman PE, Klotman.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
CoRPS Center of Research on Psychology in Somatic diseases Brief Depression Screening with the PHQ-2 Predicts Poor Prognosis following PCI with Drug-Eluting.
Effects of Alcohol and Crack Cocaine Use on Virological and Immunological Disease Progression in a Cohort of U.S. Women with HIV/AIDS Judith A. Cook, Ph.D.
Slideset on: Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving.
San Antonio Breast Cancer Symposium – December 6-10, 2016
What should the Systolic BP treatment goal be in patients with CKD?
Nephrology Journal Club The SPRINT Trial Parker Gregg
VACS Cancer Core Robert Dubrow, PhD, MD Founding Director
Long-term alcohol use patterns and HIV disease severity in U. S
Health and Human Services National Heart, Lung, and Blood Institute
Clinical outcome after SVR: Veterans Affairs
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
Diabetes Journal Club March 17, 2011
Fung TT, et al. Circulation 2009;119:
Presenter Disclosure Information
VACS Risk Index Refinement and further validation
Shawn L Fultz, MD MPH VACS Scientific Meeting, Feb 2004
Liver Injury is Associated with ASCVD, Stroke, and CHF
Melissa Herrin, Jan Tate ScD, MPH & Amy Justice, MD, PhD
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
Core Competency 1: Epidemiologic Background of HIV/HCV Co-infection in the United States Lesson 2: Morbidity and Mortality in HCV Co-infected People Living.
Presentation transcript:

HIV infection and cardiovascular diseases Matthew S. Freiberg, MD, MSc University of Pittsburgh School of Medicine and Graduate School of Public Health Yale GIM Research in Progress September 8 th, 2011

DISCLOSURE & ACCREDITATION This Grand Rounds is accredited for CME by the Yale School of Medicine. If you wish to receive credit for your participation, you must:  sign in

DISCLOSURE & ACCREDITATION Acknowledgement is made on behalf of the Department that: ~ There is no commercial support for this Grand Rounds. Confirmation is also made that today’s lecture and faculty disclosure have been peer reviewed and: ~There are no conflicts of interest.

By 2015, what percentage of HIV infected people living in the U.S. will be 50 years of age or older 15% 25% 35% 50%

By 2015, what percentage of HIV infected people living in the U.S. will be 50 years of age or older 15% 25% 35% 50%

At the end of 2006, African Americans accounted for what percentage of all new HIV infection diagnoses 15% 35% 45% 50%

At the end of 2006, African Americans accounted for what percentage of all new HIV infection diagnoses 15% 35% 45% 50%

In 2006, the rate of new HIV infection for black women was nearly __ times as high as that of white women and nearly __ times that of Hispanic/Latina women. 3 and 2 5 and 3 10 and 3 15 and 4

In 2006, the rate of new HIV infection for black women was nearly __ times as high as that of white women and nearly __ times that of Hispanic/Latina women. 3 and 2 5 and 3 10 and 3 15 and 4

Background HIV infection is associated with –Increased coronary calcium 1 –Progression of carotid IMT 2 –Endothelial dysfunction as measured by FMD 3 Antiretroviral therapy (ARV) is associated with AMI risk in observational studies 4 Intermittent ARV, however, is associated with a greater risk of AMI than continuous ARV for viral suppression 5 1. Lai et al. Archives of Internal Medicine 2005; 2. Hsue et al. Circulation 2004; 3. Solages et al. CID 2006; 4. DAD study group. NEJM 2007; 5. SMART study group. NEJM 2006.

11 The SMART Study The Strategies for Management of ART (SMART) study is a RCT of 5472 HIV+ Participants who were assigned either to drug Conservation or viral suppression Participants were followed for 16 months Primary end points was opportunistic disease or death from any cause (n=167) Secondary endpoints were major CVD, renal, or hepatic disease (n=104 of which 79 were CVD)

12 The SMART Study The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. N Engl J Med 2006;355:

Important Questions Is HIV infection an independent risk factor for AMI? Does HIV infection increase the risk of other cardiovascular diseases? If HIV does increase the risk of CVD what is the mechanism? Do ARVs play a role? Do non-traditional risk factors play a role? If so, does the Framingham risk score apply to those with HIV infection?

Is HIV as an independent risk factor for AMI

Prior studies suggesting HIV is associated with a significant AMI risk Triant et al. 1 –AMI rate ratio=1.75 (95% CI= , p<0.001) Klein et al. 2 –AMI rate ratio=1.4 (95% CI= , p<0.001) Obel et al. 3 –IHD hospitalization RR=2.12 (95% CI= ) Currier et al. 4 –CHD RR=2.16 (95% CI= ) for men –CHD RR=1.53 (95% CI= ) for women Triant et al. J Clin Endo Metab 2007; 2. Klein et al. CROI. Boston, 2011; 3. Odell et al. CID Currier et al. JAIDS 2003

Veterans Aging Cohort Study Virtual Cohort and Ischemic Heart Disease Quality Enhance Research Initiative Cohort of HIV+ and 1:2 matched age, gender, race/ethnicity, and clinical site matched Veterans All participants alive in 2003 eligible and free of baseline CVD (n=84,832, 33% HIV+) All AMI outcomes clinically confirmed by IHD QUERI Validated smoking data, blood pressure and lipid measurements were used

Freiberg et al. CROI. Boston, 2011

HIV and the risk of AMI in subpopulations Among never smokers (HR=2.82, 95% CI= ) Among those not on Statin therapy (HR=1.88, 95% CI= ) Among those without hepatitis C, renal disease, or obesity (HR=1.82, 95% CI= ) Freiberg et al. CROI. Boston, 2011

HIV and HCV Co-infection and the Risk of Incident CHD * Incidence rates are age and race/ethnicity adjusted per 1000 person-years Model 1 adjusted for age, race/ethnicity, education, BMI, traditional CHD risk factors, and substance use Model 2 adjusted for all in model 1 plus competing risk of death Freiberg et al. Circ Cardiovascular Quality and Outcomes, in press

HCV, ARV, and the risk of AMI among HIV infected men ‡Models adjusted for age, race/ethnicity, education, BMI, traditional CHD risk factors, and substance use Class of ARV (either duration or recent use), HIV viral load, CD4 count, and adjustment for death as a Censoring event or a competing risk Freiberg et al. Circ Cardiovascular Quality and Outcomes, in press

Does HIV infection increase the risk of other cardiovascular diseases?

2 Increasing incidence of ischemic stroke in patients with HIV Figure 1 Trends in stroke hospitalization by type among persons with a diagnosis of HIV in the United States population (A) Ischemic stroke: trend p value p value = (C) Intracerebral hemorrhage: trend p value = Ovbiagele et al. Neurology 2011

Alcohol Abuse or Dependence, HIV, and the Risk of Incident Ischemic Stroke Incidence rates are age and race/ethnicity adjusted per 1000 person-years Model adjusted for age, race/ethnicity, education, CVD risk factors, hepatitis C; and DX of cocaine abuse or dependence Freiberg et al. Research Society on Alcoholism Conference, San Antonio, 2010

Which of the following is NOT true about HIV and failure HIV is associated with a nearly two fold increased risk of heart failure Ongoing HIV viral replication may play a role HIV is not associated with heart failure after adjusting for CHD, ischemic cardiomyopathy, and hazardous alcohol consumption

Which of the following is NOT true about HIV and failure HIV is associated with a nearly two fold increased risk of heart failure Ongoing HIV viral replication may play a role HIV is not associated with heart failure after adjusting for CHD, ischemic cardiomyopathy, and hazardous alcohol consumption

HIV and the Risk of Heart Failure Butt et al. Archives of Internal Medicine, 2011

HIV and the Risk of Heart Failure by viral load status Butt et al. Archives of Internal Medicine, 2011

Echocardiographic Parameters by HIV Status Hsue et al. Circ Heart Failure 2010

HIV infection is associated with diastolic dysfunction Hsue et al. Circ Heart Failure 2010

If HIV does increase the risk of CVD what is the mechanism? Do ARVs play a role?

Conceptual Model for HIV and Vascular Risk Baker et al. European Heart Journal 2011

Chronic HIV infection and microbial translocation Brenchley et al. Nature Medicine 2006

Microbial translocation and mortality among HIV infected people* Sandler et al. JID *No adjustment for liver disease or alcohol

Biomarkers associated with Fatal and Non-Fatal CVD from the SMART Study Hs CRP HR=1.6 (95% CI= ) p=0.20 IL-6 HR=2.8 (95% CI= ) p=0.003 Amyloid A HR=1.6 (95% CI= ) p=0.12 Amyloid P HR=2.8 (95% CI= ) p=0.002 D-dimer HR=2.0 (95% CI= ) p=0.06 Kuller et al. CROI. Boston, 2008

2 Biomarkers associated with CVD risk among those chronically infected with HIV Ford et al. AIDS 2010

2 ART Use, Viral Suppression, and CD4 Change Over Follow-Up Baker et al. JAIDS 2011

2 Median levels of hsCRP (A), IL-6 (B), and D-dimer (C) are presented for VS and DC groups at each visit. Error bars represent the interquartile range (IQR). *P values represent the difference between treatment groups in the change from baseline (on loge scale) and are adjusted for baseline biomarker level. Baker et al. JAIDS 2011

Average change to 1 month in the DC versus VS group in total, large, medium and small HDL-p (μmol/L) by treatment group among HIV infected people. Duprez et al. Atherosclerosis 2009

ARV Therapy and Levels of Inflammatory Biomarkers Baker et al. CROI. Boston, 2011

Do non-traditional risk factors play a role?

The role of alcohol, hepatitis C, and HIV and the risk of AMI Freiberg and Kraemer. Alcohol Research and Health. 2010

Current Alcohol Consumption and HIV VL and Levels of sCD14, IL-6, D-dimer, and Fib4 Score All values are median (25 th,75 th percentiles) Freiberg et al. ISBRA Conference. Paris, 2010

HCV Status and Levels of sCD14, IL-6, D-dimer, and FIB4 Score Median values for all biomarkers, p values ≤ for all ng/mlpg/ml ug/ml Freiberg et al. ISBRA Conference. Paris, 2010

FIB4 Score and Levels of sCD14, IL-6, and D- dimer Freiberg et al. ISBRA Conference. Paris, 2010

The association between HIV and HCV viral load and biomarkers in the HIV LIVE Study Viral Load (VL) Biomarker Category HIV+ HCV+ N=127 HIV+ HCV- N=122 HIV- HCV+ N=53 HIV- HCV- N=59 P value Percentage of participants with >75 th percentile of Biomarker IL <0.01 CRP Cystatin C <0.01 SSA TNF alpha <0.01 MCP IL <0.01 INF gamma Samet et al. ISBRA Conference. Paris, 2010

Correlation between D-dimer, sCD14, IL-6 biomarkers in the VACS* * All associations are significant p<0.001

So, what might you predict next….

Characteristics of SMART, CARDIA, and MESA Study Participants. Neuhaus J et al. J Infect Dis

Median Levels and Interquartile Ranges (IQRs) of Biomarkers for SMART, CARDIA, and MESA Study Participants. Neuhaus J et al. J Infect Dis

Biomarkers Levels in SMART Study Participants Receiving Antiretroviral Therapy (ART) Who Had an HIV RNA Level ≤400 Copies/mL and Percentage Differences in Levels Versus CARDIA and MESA Study Participants Neuhaus J et al. J Infect Dis

HIV + HIV - D-dimer sCD14 IL-6 The association between biomarkers and HIV status in the VACS

Does the Framingham risk score apply to those with HIV infection? Yes but it probably overestimates the risk Yes but it probably underestimates the risk No, because middle aged Caucasians from Framingham, Massachusetts cannot generalize to an HIV population I have no idea

Does the Framingham risk score apply to those with HIV infection? Yes but it probably overestimates the risk Yes but it probably underestimates the risk No, because middle aged Caucasians from Framingham, Massachusetts cannot generalize to an HIV population I have no idea

Freiberg et al. CROI. Boston, 2011

Additional Framingham Risk Score Data Median Baseline Framingham Risk score –HIV+ 6.0 –uninfected 6.0 HIV infected Veterans have an increased risk of AMI ( HR=1.95, 95% CI= ) This risk persisted among never smokers This risk persisted among those without HCV, renal disease, or obesity

Predicting MI with the Framingham risk equation Law et al. HIV Med 2006

Important Questions Is HIV infection an independent risk factor for AMI? Does HIV infection increase the risk of other cardiovascular diseases? If HIV does increase the risk of CVD what is the mechanism? Do ARVs play a role? Do non-traditional risk factors play a role? If so, does the Framingham risk score apply to those with HIV infection?

Acknowledgements Veteran Aging Cohort Study (VACS) Participants Mentors –Amy Justice, MD, PHD –Lewis Kuller, MD, Dr.PH Project Officers –Cheryl McDonald, MD, NHLBI –Kendal Bryant, PhD, NIAAA NHLBI HL ; 03S1; 03S2 NIAAA AA S1 Project Coordinators: Carol Rogina and Glory Koerbel Collaborators: –Jason Baker MD, MPH, University of Minnesota –Russ Tracy, PhD, University of Vermont –Jeffrey Samet, MD, MA, MPH, Boston University

2 Cardiovascular and metabolic markers before and after a median of 8 months of combination antiretroviral therapy and their correlation with HIV-RNA before combination antiretroviral therapy. Calmy et al. AIDS 2009.

Correlation of Lipid Measures with Human Immunodeficiency Virus (HIV) RNA and Biomarkers among HIV-Infected Participants. Baker J et al. J Infect Dis